Last 12 months
Inside the activity.
0 purchase rows · 15 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 2 |
| Dec 2025 | 0 | 2 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 2 |
| May 2026 | 0 | 6 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 1 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 2 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 10, 2017 Filed Mar 10, 2017 22:48 UTC |
El-Hibri FuadDirector · Chairman · 10% owner
|
Exercise / conversionRestrictive Stock Units · Derivative | 20,554 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-007180 · doc4.xml · derivative · entry 8 El-Hibri Fuad · CIK 0001380185 · Director · Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,064 Underlying: Common Stock · 20,554 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · security: In connection with the Issuer's spin-off of Aptevo Therapeutics Inc. effective on August 1, 2016 (the "Spin-off"), the Issuer made certain adjustments to the price and number of equity awards held by the Issuer's continuing employees. Accordingly, Mr. El-Hibri received an equitable adjustment to the number and grant price of his restricted stock units. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F6 · derivative.exercise_date: On March 11, 2014, Mr. El-Hibri was granted 61,622 restricted stock units (after giving effect to the adjustment in connection with the Spin-off) vesting in three equal annual installments beginning on the day prior to the anniversary of the grant date. F6 · derivative.expiration_date: On March 11, 2014, Mr. El-Hibri was granted 61,622 restricted stock units (after giving effect to the adjustment in connection with the Spin-off) vesting in three equal annual installments beginning on the day prior to the anniversary of the grant date. Read SEC document |
| March 10, 2017 Filed Mar 10, 2017 22:48 UTC |
El-Hibri FuadDirector · Chairman · 10% owner
|
Tax withholdingCommon Stock | 6,089 | $31.05 | $189,063.45 |
DisclosureSEC source: 0000899243-17-007180 · doc4.xml · nonDerivative · entry 4 El-Hibri Fuad · CIK 0001380185 · Director · Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,680,216 Read SEC document |
| March 10, 2017 Filed Mar 10, 2017 22:48 UTC |
El-Hibri FuadDirector · Chairman · 10% owner
|
Exercise / conversionCommon Stock | 20,554 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-17-007180 · doc4.xml · nonDerivative · entry 3 El-Hibri Fuad · CIK 0001380185 · Director · Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,686,305 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| March 09, 2017 Filed Mar 11, 2017 02:38 UTC |
Havey AdamEVP, Biodefense Divison
|
Tax withholdingCommon Stock | 1,076 | $30.98 | $33,334.48 |
DisclosureSEC source: 0001140361-17-011684 · doc1.xml · nonDerivative · entry 1 Havey Adam · CIK 0001514588 · EVP, Biodefense Divison 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,889 F1 · security: Consists of restricted stock units granted under the Amended and Restated Emergent BioSolutions Inc. 2006 Stock Incentive Plan, as amended. Read SEC document |
| March 09, 2017 Filed Mar 11, 2017 02:30 UTC |
Kramer RobertEVP, Corproate Services Div
|
Tax withholdingCommon Stock | 1,908 | $30.98 | $59,109.84 |
DisclosureSEC source: 0001140361-17-011682 · doc1.xml · nonDerivative · entry 1 Kramer Robert · CIK 0001380956 · EVP, Corproate Services Div 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,102 F1 · security: Consists of restricted stock units granted under the Amended and Restated Emergent BioSolutions Inc. 2006 Stock Incentive Plan, as amended. Read SEC document |
| March 09, 2017 Filed Mar 11, 2017 02:10 UTC |
Abdun-Nabi DanielDirector · President & CEO
|
Tax withholdingCommon Stock | 8,226 | $30.98 | $254,841.48 |
DisclosureSEC source: 0001140361-17-011680 · doc1.xml · nonDerivative · entry 1 Abdun-Nabi Daniel · CIK 0001380187 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 214,872 F1 · security: Consists of restricted stock units granted under the Amended and Restated Emergent BioSolutions Inc. 2006 Stock Incentive Plan, as amended. Read SEC document |
| March 09, 2017 Filed Mar 10, 2017 22:48 UTC |
El-Hibri FuadDirector · Chairman · 10% owner
|
Exercise / conversionRestrictive Stock Units · Derivative | 13,236 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-007180 · doc4.xml · derivative · entry 7 El-Hibri Fuad · CIK 0001380185 · Director · Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,618 Underlying: Common Stock · 13,236 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · security: In connection with the Issuer's spin-off of Aptevo Therapeutics Inc. effective on August 1, 2016 (the "Spin-off"), the Issuer made certain adjustments to the price and number of equity awards held by the Issuer's continuing employees. Accordingly, Mr. El-Hibri received an equitable adjustment to the number and grant price of his restricted stock units. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F5 · derivative.exercise_date: On March 10, 2015, Mr. El-Hibri was granted 39,709 restricted stock units (after giving effect to the adjustment in connection with the Spin-off) vesting in three equal annual installments beginning on the day prior to the anniversary of the grant date. F5 · derivative.expiration_date: On March 10, 2015, Mr. El-Hibri was granted 39,709 restricted stock units (after giving effect to the adjustment in connection with the Spin-off) vesting in three equal annual installments beginning on the day prior to the anniversary of the grant date. Read SEC document |
| March 09, 2017 Filed Mar 10, 2017 22:48 UTC |
El-Hibri FuadDirector · Chairman · 10% owner
|
Tax withholdingCommon Stock | 3,621 | $30.98 | $112,178.58 |
DisclosureSEC source: 0000899243-17-007180 · doc4.xml · nonDerivative · entry 2 El-Hibri Fuad · CIK 0001380185 · Director · Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,665,751 Read SEC document |
| March 09, 2017 Filed Mar 10, 2017 22:48 UTC |
El-Hibri FuadDirector · Chairman · 10% owner
|
Exercise / conversionCommon Stock | 13,236 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-17-007180 · doc4.xml · nonDerivative · entry 1 El-Hibri Fuad · CIK 0001380185 · Director · Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,669,372 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| March 08, 2017 Filed Mar 10, 2017 16:18 UTC |
Hauer Jerome MDirector
|
SaleCommon Stock | 2,576 | $31.27 | $80,558.48 |
DisclosureSEC source: 0001140361-17-011623 · doc1.xml · nonDerivative · entry 4 Hauer Jerome M · CIK 0001294935 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,009 F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.25 to $31.32, inclusive. Read SEC document |
| February 28, 2017 Filed Mar 3, 2017 02:58 UTC |
Kramer RobertEVP, Corproate Services Div
|
GrantEmployee Stock Option (Right to buy) · Derivative | 32,638 | $0.00 Strike: $30.63 | $0.00 |
DisclosureSEC source: 0001140361-17-010396 · doc1.xml · derivative · entry 10 Kramer Robert · CIK 0001380956 · EVP, Corproate Services Div 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,638 Underlying: Common Stock · 32,638 shares Expires 2024-02-27 F8 · derivative.exercise_date: Consists of an option granted on 03/10/2015 under the company's stock incentive plan as amended and restated. In connection with the spin-off on August 1, 2016, the reporting person received a grant of additional stock options as a result of an adjustment to preserve the pre-spin intrinsic value of an existing stock option grant. The adjustments included an adjustment to the stock option price of the grant. Read SEC document |
| February 28, 2017 Filed Mar 3, 2017 02:58 UTC |
Kramer RobertEVP, Corproate Services Div
|
Tax withholdingCommon Stock | 1,799 | $30.63 | $55,103.37 |
DisclosureSEC source: 0001140361-17-010396 · doc1.xml · nonDerivative · entry 6 Kramer Robert · CIK 0001380956 · EVP, Corproate Services Div 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,010 Read SEC document |
| February 28, 2017 Filed Mar 3, 2017 02:58 UTC |
Kramer RobertEVP, Corproate Services Div
|
GrantCommon Stock | 8,162 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-010396 · doc1.xml · nonDerivative · entry 5 Kramer Robert · CIK 0001380956 · EVP, Corproate Services Div 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,809 F5 · shares: Consists of performance stock units granted under the Amended and Restated 2006 Emergent BioSolutions Inc. Stock Incentive Plan, as amended. Each PSU represents a right to receive one share of common stock. The PSUs vest upon achievement with respect to net income as a percentage of total revenue for the 2019 fiscal year, each as determined in accordance with GAAP, as certified by the Compensation Committee following the performance period. Read SEC document |
| February 28, 2017 Filed Mar 3, 2017 02:58 UTC |
Kramer RobertEVP, Corproate Services Div
|
GrantCommon Stock | 8,161 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-010396 · doc1.xml · nonDerivative · entry 4 Kramer Robert · CIK 0001380956 · EVP, Corproate Services Div 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,647 F4 · security: Consists of restricted stock units granted under the Amended and Restated Emergent BioSolutions Inc. 2006 Stock Incentive Plan, as amended. Read SEC document |
| February 28, 2017 Filed Mar 3, 2017 02:32 UTC |
Havey AdamEVP, Biodefense Divison
|
GrantEmployee Stock Option (right to buy · Derivative | 17,134 | $30.63 Strike: $30.63 | $524,814.42 |
DisclosureSEC source: 0001140361-17-010393 · doc1.xml · derivative · entry 4 Havey Adam · CIK 0001514588 · EVP, Biodefense Divison 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,134 Underlying: Common Stock · 17,134 shares Expires 2024-02-27 F4 · derivative.exercise_date: Vests in three equal installments on February 27, 2018, February 27, 2019 and February 27, 2020. Read SEC document |
| February 28, 2017 Filed Mar 3, 2017 02:32 UTC |
Havey AdamEVP, Biodefense Divison
|
Tax withholdingCommon Stock | 938 | $30.63 | $28,730.94 |
DisclosureSEC source: 0001140361-17-010393 · doc1.xml · nonDerivative · entry 3 Havey Adam · CIK 0001514588 · EVP, Biodefense Divison 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,965 F1 · security: Consists of restricted stock units granted under the Amended and Restated Emergent BioSolutions Inc. 2006 Stock Incentive Plan, as amended. Read SEC document |
| February 28, 2017 Filed Mar 3, 2017 02:32 UTC |
Havey AdamEVP, Biodefense Divison
|
GrantCommon Stock | 4,285 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-010393 · doc1.xml · nonDerivative · entry 2 Havey Adam · CIK 0001514588 · EVP, Biodefense Divison 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,903 F3 · shares: Consists of performance stock units granted under the Amended and Restated 2006 Emergent BioSolutions Inc. Stock Incentive Plan, as amended. Each PSU represents a right to receive one share of common stock. The PSUs vest upon achievement with respect to net income as a percentage of total revenue for the 2019 fiscal year, each as determined in accordance with GAAP, as certified by the Compensation Committee following the performance period. Read SEC document |
| February 28, 2017 Filed Mar 3, 2017 02:32 UTC |
Havey AdamEVP, Biodefense Divison
|
GrantCommon Stock | 4,285 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-010393 · doc1.xml · nonDerivative · entry 1 Havey Adam · CIK 0001514588 · EVP, Biodefense Divison 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,618 F1 · security: Consists of restricted stock units granted under the Amended and Restated Emergent BioSolutions Inc. 2006 Stock Incentive Plan, as amended. F2 · shares: These restricted stock units vest in three equal annual installments beginning on the day prior to the first anniversary of the date of grant, assuming continued service with the company. Each restricted stock unit represents the right of the Reporting Person to receive one share of common stock of Emergent BioSolutions Inc., subject to adjustment as provided in the grant agreement. Read SEC document |
| February 28, 2017 Filed Mar 3, 2017 01:58 UTC |
El-Hibri FuadDirector · Chairman · 10% owner
|
GrantEmployee Stock Option (right to buy) · Derivative | 58,747 | $0.00 Strike: $30.63 | $0.00 |
DisclosureSEC source: 0000899243-17-006216 · doc4.xml · derivative · entry 7 El-Hibri Fuad · CIK 0001380185 · Director · Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,747 Underlying: Common Stock · 58,747 shares Expires 2024-02-27 F7 · derivative.exercise_date: On February 28, 2017, Mr. El-Hibri was granted 58,747 stock options vesting in three equal annual installments beginning on the day prior to the anniversary of the grant date. Read SEC document |
| February 28, 2017 Filed Mar 3, 2017 01:58 UTC |
El-Hibri FuadDirector · Chairman · 10% owner
|
Exercise / conversionRestrictive Stock Units · Derivative | 9,722 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-006216 · doc4.xml · derivative · entry 6 El-Hibri Fuad · CIK 0001380185 · Director · Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,854 Underlying: Common Stock · 9,722 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · security: In connection with the Issuer's spin-off of Aptevo Therapeutics Inc. effective on August 1, 2016 (the "Spin-off"), the Issuer made certain adjustments to the price and number of equity awards held by continuing employees. Accordingly, Mr. El-Hibri, as a continuing Emergent employee with equity awards issued prior to the Spin-off, received an equitable adjustment to the number and grant price of his restricted stock units. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F6 · derivative.exercise_date: On March 1, 2016, Mr. El-Hibri was granted 29,167 restricted stock units (after giving effect to the adjustment in connection with the Spin-off) vesting in three equal annual installments beginning on the day prior to the anniversary of the grant date. F6 · derivative.expiration_date: On March 1, 2016, Mr. El-Hibri was granted 29,167 restricted stock units (after giving effect to the adjustment in connection with the Spin-off) vesting in three equal annual installments beginning on the day prior to the anniversary of the grant date. Read SEC document |
| February 28, 2017 Filed Mar 3, 2017 01:58 UTC |
El-Hibri FuadDirector · Chairman · 10% owner
|
GrantRestrictive Stock Units · Derivative | 29,382 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-006216 · doc4.xml · derivative · entry 5 El-Hibri Fuad · CIK 0001380185 · Director · Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,576 Underlying: Common Stock · 29,382 shares Expires not disclosed F4 · security: In connection with the Issuer's spin-off of Aptevo Therapeutics Inc. effective on August 1, 2016 (the "Spin-off"), the Issuer made certain adjustments to the price and number of equity awards held by continuing employees. Accordingly, Mr. El-Hibri, as a continuing Emergent employee with equity awards issued prior to the Spin-off, received an equitable adjustment to the number and grant price of his restricted stock units. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F5 · derivative.exercise_date: On February 28, 2017, Mr. El-Hibri was granted 29,382 restricted stock units vesting in three equal annual installments beginning on the day prior to the anniversary of the grant date. F5 · derivative.expiration_date: On February 28, 2017, Mr. El-Hibri was granted 29,382 restricted stock units vesting in three equal annual installments beginning on the day prior to the anniversary of the grant date. Read SEC document |
| February 28, 2017 Filed Mar 3, 2017 01:58 UTC |
El-Hibri FuadDirector · Chairman · 10% owner
|
Tax withholdingCommon Stock | 2,659 | $30.63 | $81,445.17 |
DisclosureSEC source: 0000899243-17-006216 · doc4.xml · nonDerivative · entry 2 El-Hibri Fuad · CIK 0001380185 · Director · Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,656,136 Read SEC document |
| February 28, 2017 Filed Mar 3, 2017 01:58 UTC |
El-Hibri FuadDirector · Chairman · 10% owner
|
Exercise / conversionCommon Stock | 9,722 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-17-006216 · doc4.xml · nonDerivative · entry 1 El-Hibri Fuad · CIK 0001380185 · Director · Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,658,795 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| February 28, 2017 Filed Mar 3, 2017 02:29 UTC |
Abdun-Nabi DanielDirector · President & CEO
|
GrantEmployee Stock Option (right to buy) · Derivative | 78,329 | $30.63 Strike: $30.63 | $2,399,217.27 |
DisclosureSEC source: 0001140361-17-010390 · doc1.xml · derivative · entry 4 Abdun-Nabi Daniel · CIK 0001380187 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,329 Underlying: Common Stock · 78,329 shares Expires 2024-02-27 F4 · derivative.exercise_date: Vests in three equal installments on February 27, 2018, February 27, 2019 and February 27, 2020. Read SEC document |
| February 28, 2017 Filed Mar 3, 2017 02:29 UTC |
Abdun-Nabi DanielDirector · President & CEO
|
Tax withholdingCommon Stock | 6,184 | $30.63 | $189,415.92 |
DisclosureSEC source: 0001140361-17-010390 · doc1.xml · nonDerivative · entry 3 Abdun-Nabi Daniel · CIK 0001380187 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 223,098 F1 · security: Consists of restricted stock units granted under the Amended and Restated Emergent BioSolutions Inc. 2006 Stock Incentive Plan, as amended. Read SEC document |
| February 28, 2017 Filed Mar 3, 2017 02:29 UTC |
Abdun-Nabi DanielDirector · President & CEO
|
GrantCommon Stock | 19,589 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-010390 · doc1.xml · nonDerivative · entry 2 Abdun-Nabi Daniel · CIK 0001380187 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 229,282 F3 · shares: Consists of performance stock units granted under the Amended and Restated 2006 Emergent BioSolutions Inc. Stock Incentive Plan, as amended. Each PSU represents a right to receive one share of common stock. The PSUs vest upon achievement with respect to net income as a percentage of total revenue for the 2019 fiscal year, each as determined in accordance with GAAP, as certified by the Compensation Committee following the performance period. Read SEC document |
| February 28, 2017 Filed Mar 3, 2017 02:29 UTC |
Abdun-Nabi DanielDirector · President & CEO
|
GrantCommon Stock | 19,588 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-010390 · doc1.xml · nonDerivative · entry 1 Abdun-Nabi Daniel · CIK 0001380187 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 209,693 F1 · security: Consists of restricted stock units granted under the Amended and Restated Emergent BioSolutions Inc. 2006 Stock Incentive Plan, as amended. F2 · shares: These restricted stock units vest in three equal annual installments beginning on the day prior to the first anniversary of the date of grant, assuming continued service with the company. Each restricted stock unit represents the right of the Reporting Person to receive one share of common stock of Emergent BioSolutions Inc., subject to adjustment as provided in the grant agreement. Read SEC document |
| February 27, 2017 Filed Mar 2, 2017 01:26 UTC |
Abdun-Nabi DanielDirector · President & CEO
|
Exercise / conversionStock Option - (Right to Buy) · Derivative | 3,662 | $0.00 Strike: $14.51 | $0.00 |
DisclosureSEC source: 0001140361-17-010111 · doc1.xml · derivative · entry 4 Abdun-Nabi Daniel · CIK 0001380187 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 3,662 shares Expires 2017-03-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Consists of options granted under the Amended and Restated Emergent BioSolutions Inc 2006 Stock Incentive Plan, as amended. F2 · derivative.exercise_date: The option vested in three equal installments in March 2011, March 2012 and March 2013. Read SEC document |
| February 27, 2017 Filed Mar 2, 2017 01:26 UTC |
Abdun-Nabi DanielDirector · President & CEO
|
Tax withholdingCommon Stock | 984 | $30.63 | $30,139.92 |
DisclosureSEC source: 0001140361-17-010111 · doc1.xml · nonDerivative · entry 3 Abdun-Nabi Daniel · CIK 0001380187 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 190,105 F1 · security: Consists of options granted under the Amended and Restated Emergent BioSolutions Inc 2006 Stock Incentive Plan, as amended. F4 · shares: Consists of shares withheld from the option exercise and delivered to the issuer to satisfy the reporting persons tax withholding obligations. Read SEC document |
| February 27, 2017 Filed Mar 2, 2017 01:26 UTC |
Abdun-Nabi DanielDirector · President & CEO
|
Tax withholdingCommon Stock | 1,735 | $30.63 | $53,143.05 |
DisclosureSEC source: 0001140361-17-010111 · doc1.xml · nonDerivative · entry 2 Abdun-Nabi Daniel · CIK 0001380187 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 191,089 F1 · security: Consists of options granted under the Amended and Restated Emergent BioSolutions Inc 2006 Stock Incentive Plan, as amended. F3 · shares: Consists of shares owned by the reporting person and delivered to the issuer to satisfy the reporting persons exercise price for the reported stock options. Read SEC document |
| February 27, 2017 Filed Mar 2, 2017 01:26 UTC |
Abdun-Nabi DanielDirector · President & CEO
|
Exercise / conversionCommon Stock | 3,662 | $30.63 | $112,167.06 |
DisclosureSEC source: 0001140361-17-010111 · doc1.xml · nonDerivative · entry 1 Abdun-Nabi Daniel · CIK 0001380187 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 192,824 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Consists of options granted under the Amended and Restated Emergent BioSolutions Inc 2006 Stock Incentive Plan, as amended. Read SEC document |
| January 17, 2017 Filed Jan 19, 2017 21:33 UTC |
Bailey SueDirector
|
Exercise / conversionStock Option (Right to buy) · Derivative | 2,061 | $0.00 Strike: $18.64 | $0.00 |
DisclosureSEC source: 0001140361-17-002344 · doc1.xml · derivative · entry 27 Bailey Sue · CIK 0001403769 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,244 Underlying: Common Stock · 2,061 shares Expires 2021-05-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · security: Consists of an option granted under the company's stock incentive plan as amended and restated. The grant was made prior to the spin-off. F4 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by Dr. Bailey. F8 · derivative.exercise_date: The option grant vests in three equal installments on the day prior to the first, second and third anniversary dates of the grant. Read SEC document |
| January 17, 2017 Filed Jan 19, 2017 21:33 UTC |
Bailey SueDirector
|
Exercise / conversionStock Option (Right to buy) · Derivative | 3,157 | $0.00 Strike: $13.00 | $0.00 |
DisclosureSEC source: 0001140361-17-002344 · doc1.xml · derivative · entry 25 Bailey Sue · CIK 0001403769 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,736 Underlying: Common Stock · 3,157 shares Expires 2020-05-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · security: Consists of an option granted under the company's stock incentive plan as amended and restated. The grant was made prior to the spin-off. F4 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by Dr. Bailey. F8 · derivative.exercise_date: The option grant vests in three equal installments on the day prior to the first, second and third anniversary dates of the grant. Read SEC document |
| January 17, 2017 Filed Jan 19, 2017 21:33 UTC |
Bailey SueDirector
|
Exercise / conversionStock Option (Right to buy) · Derivative | 4,735 | $0.00 Strike: $13.37 | $0.00 |
DisclosureSEC source: 0001140361-17-002344 · doc1.xml · derivative · entry 23 Bailey Sue · CIK 0001403769 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,158 Underlying: Common Stock · 4,735 shares Expires 2019-05-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · security: Consists of an option granted under the company's stock incentive plan as amended and restated. The grant was made prior to the spin-off. F4 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by Dr. Bailey. F8 · derivative.exercise_date: The option grant vests in three equal installments on the day prior to the first, second and third anniversary dates of the grant. Read SEC document |
| January 17, 2017 Filed Jan 19, 2017 21:33 UTC |
Bailey SueDirector
|
Exercise / conversionStock Option (Right to buy) · Derivative | 3,157 | $0.00 Strike: $20.08 | $0.00 |
DisclosureSEC source: 0001140361-17-002344 · doc1.xml · derivative · entry 21 Bailey Sue · CIK 0001403769 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,579 Underlying: Common Stock · 3,157 shares Expires 2021-05-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · security: Consists of an option granted under the company's stock incentive plan as amended and restated. The grant was made prior to the spin-off. F4 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by Dr. Bailey. F8 · derivative.exercise_date: The option grant vests in three equal installments on the day prior to the first, second and third anniversary dates of the grant. Read SEC document |
| January 17, 2017 Filed Jan 19, 2017 21:33 UTC |
Bailey SueDirector
|
Exercise / conversionStock Option (Right to buy) · Derivative | 3,157 | $0.00 Strike: $14.71 | $0.00 |
DisclosureSEC source: 0001140361-17-002344 · doc1.xml · derivative · entry 19 Bailey Sue · CIK 0001403769 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,157 shares Expires 2020-05-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · security: Consists of an option granted under the company's stock incentive plan as amended and restated. The grant was made prior to the spin-off. F4 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by Dr. Bailey. F8 · derivative.exercise_date: The option grant vests in three equal installments on the day prior to the first, second and third anniversary dates of the grant. Read SEC document |
| January 17, 2017 Filed Jan 19, 2017 21:33 UTC |
Bailey SueDirector
|
Exercise / conversionStock Option (Right to buy) · Derivative | 3,157 | $0.00 Strike: $10.64 | $0.00 |
DisclosureSEC source: 0001140361-17-002344 · doc1.xml · derivative · entry 17 Bailey Sue · CIK 0001403769 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,157 shares Expires 2019-05-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · security: Consists of an option granted under the company's stock incentive plan as amended and restated. The grant was made prior to the spin-off. F4 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by Dr. Bailey. F8 · derivative.exercise_date: The option grant vests in three equal installments on the day prior to the first, second and third anniversary dates of the grant. Read SEC document |
| January 17, 2017 Filed Jan 19, 2017 21:33 UTC |
Bailey SueDirector
|
SaleCommon Stock | 2,061 | $29.78 | $61,374.31 |
DisclosureSEC source: 0001140361-17-002344 · doc1.xml · nonDerivative · entry 15 Bailey Sue · CIK 0001403769 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,818 F4 · shares: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by Dr. Bailey. Read SEC document |
| January 17, 2017 Filed Jan 19, 2017 21:33 UTC |
Bailey SueDirector
|
Exercise / conversionCommon Stock | 2,061 | $18.64 | $38,417.04 |
DisclosureSEC source: 0001140361-17-002344 · doc1.xml · nonDerivative · entry 14 Bailey Sue · CIK 0001403769 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,879 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · shares: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by Dr. Bailey. Read SEC document |
| January 17, 2017 Filed Jan 19, 2017 21:33 UTC |
Bailey SueDirector
|
SaleCommon Stock | 3,157 | $29.78 | $94,011.99 |
DisclosureSEC source: 0001140361-17-002344 · doc1.xml · nonDerivative · entry 13 Bailey Sue · CIK 0001403769 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,818 F4 · shares: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by Dr. Bailey. F5 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.50 to $30.68, inclusive. Read SEC document |
| January 17, 2017 Filed Jan 19, 2017 21:33 UTC |
Bailey SueDirector
|
Exercise / conversionCommon Stock | 3,157 | $13.00 | $41,041.00 |
DisclosureSEC source: 0001140361-17-002344 · doc1.xml · nonDerivative · entry 12 Bailey Sue · CIK 0001403769 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,975 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · shares: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by Dr. Bailey. Read SEC document |
| January 17, 2017 Filed Jan 19, 2017 21:33 UTC |
Bailey SueDirector
|
SaleCommon Stock | 4,735 | $29.78 | $141,003.09 |
DisclosureSEC source: 0001140361-17-002344 · doc1.xml · nonDerivative · entry 11 Bailey Sue · CIK 0001403769 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,818 F4 · shares: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by Dr. Bailey. F5 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.50 to $30.68, inclusive. Read SEC document |
| January 17, 2017 Filed Jan 19, 2017 21:33 UTC |
Bailey SueDirector
|
Exercise / conversionCommon Stock | 4,735 | $13.37 | $63,306.95 |
DisclosureSEC source: 0001140361-17-002344 · doc1.xml · nonDerivative · entry 10 Bailey Sue · CIK 0001403769 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,553 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · shares: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by Dr. Bailey. Read SEC document |
| January 17, 2017 Filed Jan 19, 2017 21:33 UTC |
Bailey SueDirector
|
SaleCommon Stock | 3,157 | $29.78 | $94,011.99 |
DisclosureSEC source: 0001140361-17-002344 · doc1.xml · nonDerivative · entry 9 Bailey Sue · CIK 0001403769 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,818 F4 · shares: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by Dr. Bailey. F5 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.50 to $30.68, inclusive. Read SEC document |
| January 17, 2017 Filed Jan 19, 2017 21:33 UTC |
Bailey SueDirector
|
Exercise / conversionCommon Stock | 3,157 | $20.08 | $63,392.56 |
DisclosureSEC source: 0001140361-17-002344 · doc1.xml · nonDerivative · entry 8 Bailey Sue · CIK 0001403769 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,975 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · shares: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by Dr. Bailey. Read SEC document |
| January 17, 2017 Filed Jan 19, 2017 21:33 UTC |
Bailey SueDirector
|
SaleCommon Stock | 3,157 | $29.78 | $94,011.99 |
DisclosureSEC source: 0001140361-17-002344 · doc1.xml · nonDerivative · entry 7 Bailey Sue · CIK 0001403769 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,818 F4 · shares: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by Dr. Bailey. F5 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.50 to $30.68, inclusive. Read SEC document |
| January 17, 2017 Filed Jan 19, 2017 21:33 UTC |
Bailey SueDirector
|
Exercise / conversionCommon Stock | 3,157 | $14.71 | $46,439.47 |
DisclosureSEC source: 0001140361-17-002344 · doc1.xml · nonDerivative · entry 6 Bailey Sue · CIK 0001403769 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,975 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · shares: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by Dr. Bailey. Read SEC document |
| January 17, 2017 Filed Jan 19, 2017 21:33 UTC |
Bailey SueDirector
|
SaleCommon Stock | 3,157 | $29.78 | $94,011.99 |
DisclosureSEC source: 0001140361-17-002344 · doc1.xml · nonDerivative · entry 5 Bailey Sue · CIK 0001403769 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,818 F4 · shares: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by Dr. Bailey. F5 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.50 to $30.68, inclusive. Read SEC document |
| January 17, 2017 Filed Jan 19, 2017 21:33 UTC |
Bailey SueDirector
|
Exercise / conversionCommon Stock | 3,157 | $10.64 | $33,590.48 |
DisclosureSEC source: 0001140361-17-002344 · doc1.xml · nonDerivative · entry 4 Bailey Sue · CIK 0001403769 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,975 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · shares: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by Dr. Bailey. Read SEC document |
| January 17, 2017 Filed Jan 20, 2017 02:15 UTC |
Havey AdamEVP, Biodefense Divison
|
SaleCommon Stock | 8,438 | $29.75 | $251,000.97 |
DisclosureSEC source: 0001140361-17-002340 · doc1.xml · nonDerivative · entry 4 Havey Adam · CIK 0001514588 · EVP, Biodefense Divison 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,333 F4 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Mr. Havey. F5 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.48 to $30.15, inclusive. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.